Human cytomegalovirus and primary intracranial tumours: frequency of tumour infection and lack of correlation with systemic immune anti-viral responses

Authors

  • E. Bianchi,

    1. Department of Anatomopathology, Laboratory of Neuropathology, University Hospital, University of Liège, Liège, Belgium
    2. GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium
    Search for more papers by this author
  • P. Roncarati,

    1. Laboratory of Experimental Pathology, GIGA-Cancer (Center for Experimental Cancer Research), University of Liège, Liège, Belgium
    Search for more papers by this author
  • O. Hougrand,

    1. Department of Anatomopathology, Laboratory of Neuropathology, University Hospital, University of Liège, Liège, Belgium
    Search for more papers by this author
  • V. Guérin-El Khourouj,

    1. Laboratory of Immunology, Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, University Paris VII, Paris, France
    Search for more papers by this author
  • R. Boreux,

    1. Laboratory of Clinical Microbiology, University Hospital, University of Liège, Liège, Belgium
    Search for more papers by this author
  • J. Kroonen,

    1. Human Genetics, University Hospital, University of Liège, Liège, Belgium
    2. The T&P Bohnenn Laboratory for Neuro-Oncology, Department of Neurosurgery, UMC Utrecht, Utrecht, The Netherlands
    Search for more papers by this author
  • D. Martin,

    1. Department of Neurosurgery, University Hospital, University of Liège, Liège, Belgium
    Search for more papers by this author
  • P. Robe,

    1. Human Genetics, University Hospital, University of Liège, Liège, Belgium
    2. GIGA Research Center, University Hospital, University of Liège, Liège, Belgium
    3. Department of Neurosurgery and Integrated Cancer Center, University Medical Center of Utrecht, Utrecht, The Netherlands
    Search for more papers by this author
  • B. Rogister,

    1. GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium
    2. Department of Neurology, University Hospital, University of Liège, Liège, Belgium
    3. GIGA-Development, Stem Cells and Regenerative Medicine, University of Liège, Liège, Belgium
    Search for more papers by this author
  • P. Delvenne,

    Corresponding author
    1. Department of Anatomopathology, Laboratory of Neuropathology, University Hospital, University of Liège, Liège, Belgium
    2. Laboratory of Experimental Pathology, GIGA-Cancer (Center for Experimental Cancer Research), University of Liège, Liège, Belgium
    • Correspondence: Philippe Delvenne, Department of Anatomopathology, University Hospital of Liège, B-4000 Liège, Belgium. Tel: +32 04 366 2511; Fax: +32 04 366 2919; E-mail: p.delvenne@ulg.ac.be

    Search for more papers by this author
  • M. Deprez

    1. Department of Anatomopathology, Laboratory of Neuropathology, University Hospital, University of Liège, Liège, Belgium
    2. GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium
    Search for more papers by this author
    • Dr Deprez, one of the co-authors, recently passed away.

  • The authors declare that there is no conflict of interest.

Abstract

Aims

Human cytomegalovirus (HCMV) is a ubiquitous beta human herpesvirus able to influence infected cell survival and proliferation and to modulate the host immune response. As there is accumulating evidence that HCMV is detected in primary intracranial astrocytic tumours, in this study we looked for the presence of HCMV in intracranial tumours and tried to correlate this eventual presence with the anti-HCMV systemic immunoreactivity and with the detection of HCMV in peripheral blood.

Methods

In this study, we analysed 43 glioblastomas (GBM), 14 oligodendrogliomas (OL) and 20 meningiomas (MG) by immunofluorescence (IF) targeting HCMV immediate early antigen (IE1) and by nested PCR (nPCR) amplifying HCMV glycoprotein B (gB).

Results

Detection of IE1 by IF showed the presence of HCMV in 70% of GBM, 57% of OL and 85% of MG, in contrast to gB nPCR, which detected HCMV in only 50% of GBM, 38% of OL and 46% of MG. Unexpectedly, HCMV DNA and antigens were detected within GBM, OL and MG of patients that exhibit negative viral serology. More surprisingly, PCR on the peripheral blood did not detect HCMV in patients with a HCMV-positive tumour.

Conclusions

Our results are in agreement with previous observations demonstrating HCMV in glial tumours and highlight the presence of HCMV in meningiomas. We also showed that anti-HCMV specific systemic immunoreactivity and detection of HCMV in peripheral blood are not predictive of HCMV presence in primary intracranial tumours.

Ancillary